neuropharmacology: hallucinogens

32
Drugs & Behavior: Hallucinogens Brian J. Piper, Ph.D. 1933-2006

Upload: brian-piper

Post on 18-Nov-2014

1.249 views

Category:

Education


7 download

DESCRIPTION

Lecture 23 from a college level neuropharmacology course taught in the spring 2012 semester by Brian J. Piper, Ph.D. ([email protected]) at Willamette University. Includes epidemiology, pharmacokinetics, of pharmacodynamics of LSD, ketamine, PCP, and peyote.

TRANSCRIPT

Page 2: Neuropharmacology: Hallucinogens

Goals

• Mescaline (I)• LSD (I)• Psilocybin (I)• Dextromethorphan

(NA)• Ketamine (II)• PCP (II)

Page 3: Neuropharmacology: Hallucinogens

Epidemiology: Past Year

Monitoring the Future: http://monitoringthefuture.org/pubs/monographs/mtf-vol1_2009.pdf

Page 4: Neuropharmacology: Hallucinogens

Epidemiology: High School

Monitoring the Future: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 5: Neuropharmacology: Hallucinogens

College Plans

Monitoring the Future: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 6: Neuropharmacology: Hallucinogens

Region

Monitoring the Future: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 7: Neuropharmacology: Hallucinogens

Ethnicity

Monitoring the Future: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 8: Neuropharmacology: Hallucinogens

Availability

Page 9: Neuropharmacology: Hallucinogens

Mescaline• Found in peyote cactus• Entheogen for Native American Church• Visual hallucinogens/synesthesia

2:50 on, 0 to 0:30ish: http://www.youtube.com/watch?v=0kraijbaLDo

Page 10: Neuropharmacology: Hallucinogens

Psilocybin

• Religious experiences for Aztecs & Mayans• Gordon Wasson is taken on “magic mushroom” trip

by Shaman Maria Sabina• Liver converts psilocybin (Pro-drug) to psilocin

Psilocybe mexicana

http://www.imaginaria.org/wasson/life.htm

1894-1995

Page 11: Neuropharmacology: Hallucinogens

Indocybin

• Indo: Indolamine/Indian• Sandoz Pharmaceuticals tests utility as

adjunct to psychotherapy

1906-2008

Albert Hoffman

Page 12: Neuropharmacology: Hallucinogens

Hasler et al. (2004). Psychopharmacology, 172,145-156.

Altered States of Consciousness

Page 13: Neuropharmacology: Hallucinogens

Healthy adults received Placebo, Very Low Dose, Low, Medium, or High Dose (315 µg/kg) of Psilocybin and rated their subjective experiences.

Hasler et al. (2004). Psychopharmacology, 172,145-156.

Page 14: Neuropharmacology: Hallucinogens

• Similarity/Difference with Schizophrenic Hallucinations• Importance of Set & Setting

Hasler et al. (2004). Psychopharmacology, 172,145-156.

Page 15: Neuropharmacology: Hallucinogens

History of LSD

• 1938: lysergic acid diethylamide synthesized by Albert Hoffman (Delysid)

• 1950’s: military tested for “truth drug”• 1961: Timothy Leary• Current: Schedule I

• Recreational Dose: 20 -80 μg• Lethal Dose: ?

Page 16: Neuropharmacology: Hallucinogens

Epidemiology of LSD

Monitoring the Future: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 17: Neuropharmacology: Hallucinogens

Adolescent Phase?

Page 18: Neuropharmacology: Hallucinogens

Serotonin Receptors: 1, 2, 3, 4, 6, and 7Key: 2A/2C

Page 19: Neuropharmacology: Hallucinogens

Individual Differences in Response to LSD

• Flies voluntarily ate LSD and their behavior rated:

• A = Resistant (Wild type), B = Sensitive (w1118), C = Resistant (w1118 P [w+]), – 1= no effect– 2= sluggish– 3= no non-prompted movements– 4= uncoordinated movements– 5= immobile

Nichols et al. (2002). Neuroscience, 115, 979-984.

Page 20: Neuropharmacology: Hallucinogens

Hallucinogen Information• Erowid is a highly popular source of drug-

information (55K/day)

Page 21: Neuropharmacology: Hallucinogens

Hallucinogen Persisting Perception Disorder

• Online study to determine frequency of HPPD

Baggott et al. (2011). Drug & Alcohol Dependence, 114, 61-67.

Page 22: Neuropharmacology: Hallucinogens

Visual experiences (non-drug) may be more common than previously thought

A small subset (1.1%) seek treatment

Baggott et al. (2011). Drug & Alcohol Dependence, 114, 61-67.

Page 23: Neuropharmacology: Hallucinogens

Hallucinogens Compared• Dimethyltryptamine (DMT): ≈0.5 hours

– Degraded by MAO• Psilocybin: intermediate• Mescaline/LSD: 6+ hours

Tryptamine

Page 24: Neuropharmacology: Hallucinogens

Hypothetical?

• What if an experienced organic chemist described the subjective effects of self-tests of hundreds of hallucinogenic substances?

• What if they also made freely available synthesis instructions?

Page 25: Neuropharmacology: Hallucinogens

Dextromethorphan

• Low doses decrease coughing.• High doses cause dissociative state (phases).• Sigma1 agonist, SERT antagonist

Dextromethorphan --------------> Dextrorphan2D6

Page 26: Neuropharmacology: Hallucinogens

Phencyclidine (PCP)

• Parke-Davis marketed as Sernyl in 1950’s • Decreases pain sensitivity and increases body

temperature & blood pressure • Strong dissociative, euphoria, reduces inhibition• NMDA anatagonist• Long-acting (≈40 hour half-life)!

Page 27: Neuropharmacology: Hallucinogens

PCP and Brain Structure

• Adult rats received 5 mg/kg of PCP for 7 days.

• Brain sections of the prefrontal cortex were examined with electron microscopy for synapses (arrowheads), b=boutons, d=dendritic shafts.

• PCP decreased spine synapses 41%.

Hajszan et al. (2006). Biological Psychiatry, 60(6), 639-644.

Page 28: Neuropharmacology: Hallucinogens

PCP and Brain Structure (continued)

• Prefrontal cortex tissue was also examined by light microscopy for one type of glia (astroglial).

• PCP increased astroglia processes by 58.8%.

Hajszan et al. (2006). Biological Psychiatry, 60(6), 639-644.

Page 29: Neuropharmacology: Hallucinogens

Ketamine

• Synthesized in 1962, Ketalar• Short-half like (3 hours)• Used with other drugs for pain• Mechanism: NMDA antagonist and sigma

agonist

Page 30: Neuropharmacology: Hallucinogens

Ketamine & Development• Rodent studies indicate that ketamine causes

programmed cell death (apoptosis)• Rhesus monkeys received therapeutic doses of

ketamine (5 mg/kg i.v.) during pregnancy or later

Brambrink et al. (2012). Anesthesiology, 116(2), 372-384.

John Olney

Page 31: Neuropharmacology: Hallucinogens

Ketamine & Development• Rodent studies indicate that ketamine causes

programmed cell death (apoptosis)• Rhesus monkeys received therapeutic doses of

ketamine (5 mg/kg i.v.) during pregnancy or later

Brambrink et al. (2012). Anesthesiology, 116(2), 372-384.

*

Page 32: Neuropharmacology: Hallucinogens

Hallucinogen Mechanism Schedule Comments

LSD 5-HT1 antagonist?,

5-HT2A/C agonistI 8 hour trips, early model of

schizophrenia, psychotherapy

Psilocybin 5-HT2A/C agonist I LSD-light, headaches

Belladona alkaloids

mACh antagonist NA Dreamy, optical

Dextromethorphan NMDA antagonist

NA Mild dissociative

Ketamine NMDA antagonistSigma agonist

II Veterinary

PCP NMDA antagonistSigma agonist, Increase dopamine

II Anesthetic, recent “schizophrenia” model